跳至主要内容
临床试验/NCT03128372
NCT03128372已完成不适用

Validation of Next Generation INVOS NIRS Cerebral and Tissue Oximeter to Measure Cerebral and Somatic Tissue Oxygen Saturation in Healthy Volunteers

Medtronic - MITG2 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2017年5月22日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
32
试验地点
2
主要终点
Validated the Next Generation Oximeter

研究概览

简要总结

This is a validation study of a near-infrared spectroscopy (NIRS) device designed to measure the cerebral tissue oxygen saturation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 46 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy, male or female subjects between the ages of 18 to ≤46 years;
  • Completion of a health screening for a medical history by a licensed physician, nurse practitioner or physician assistant;
  • Minimum weight 40kg;
  • BMI within range 18.0 - 30.0.

排除标准

  • Prior or known allergies to lidocaine (or similar pharmacologic agents, e.g., Novocain) [self-reported];
  • Prior known severe allergies to medical grade adhesive/tape (Band-Aid) [self-reported];
  • Taking any medication other than birth control [self-reported];
  • Is currently participating in, or has recently participated in (discontinued within 30 days prior to the hypoxia procedure for this study) in an investigational drug, device, or biologic study [self-reported];
  • Has a negative Allen's Test to confirm non-patency of the collateral artery [clinical assessment by PI or delegate];
  • Has made a whole blood donation or has had at least 450 ml of blood drawn within 8 weeks prior to the study procedure [self-reported];
  • Is female with a positive pregnancy test [serum or urine], or is female and is unwilling to use effective birth control between the time of screening and study procedure or is breastfeeding;
  • Has anemia [lab values specific for gender];
  • Has a history of sickle cell trait or thalassemia [self-reported];
  • Has an abnormal hemoglobin electrophoresis test [lab measurement];
  • Has a positive urine cotinine test or urine drug screen or oral ethanol test [POC testing];
  • Has a room air saturation less than 95% by pulse oximetry [measurement by PI or delegate];
  • Has a clinically significant abnormal ECG [assessment by PI or delegate];
  • Has a clinically significant abnormal pulmonary function test via spirometry [assessment by PI or delegate];
  • Has a COHb greater than 3%, or MetHb greater than 2% [measured by venous blood sample co-oximetry]

研究组 & 干预措施

Desaturation

Experimental

Volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.

干预措施: Desaturation (Device)

结局指标

主要结局

Validated the Next Generation Oximeter

时间窗: Data collected from individual participant over 4 hour timeframe.

Cerebral overall mean bias (percentage saturation) defined as the average of the differences between the regional saturation (rSO2) value and (fSO2) value obtained from simultaneous arterial and jugular venous blood samples. Cerebral trending is defined as the measurement of changes in regional saturation (rSO2) under conditions of changing fSO2. Cerebral trending mean bias is the average difference between changes in rSO2 values compared against changes in fSO2. Somatic trending mean bias is defined the same as Cerebral trending mean bias except for the location of measurement on the subjects and for Somatic trending mean bias, rS02 was compared to rSO2 on a commercially-available regional oximetry monitor. The smaller value the better performance.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Validation of Next Generation Cerebral and Tissue... | 临床试验